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Membrane micro-architectureChlorpromazine often causes severe and persistent thrombocytopenia. Several clinical studies have suggested
the presence of an as-yet-unknown mechanism in this drug-induced thrombocytopenia, by which the platelet
production from megakaryocytes may directly be affected. As we previously demonstrated in rat peritoneal
mast cells or adipocytes, chlorpromazine is amphiphilic and preferentially partitioned into the lipid bilayers of
the plasmamembrane. Therefore, it can induce some structural changes in themegakaryocytemembrane surface
and thus affect the process of thrombopoiesis. In the present study, employing the standard patch-clampwhole-cell
recording technique, we examined the effects of chlorpromazine on themembrane capacitance and Kv1.3-channel
currents in rat megakaryocytes. By electron microscopic imaging of the cellular surface, we also examined the
effects of chlorpromazine on the membrane micro-architecture of megakaryocytes. Chlorpromazine markedly de-
creased the membrane capacitance of megakaryocytes, indicating the decreased number of invaginated plasma
membranes, which was not detected by the ﬂuorescent imaging techniques. As shown by electron microscopy,
chlorpromazine actually changed the membrane micro-architecture of megakaryocytes, and was likely to halt
the process of pro-platelet formation in the cells. This drug persistently decreased the membrane capacitance
and almost totally and irreversibly inhibited the Kv1.3-channel currents in megakaryocytes. This study demon-
strated for the ﬁrst time that chlorpromazine is likely to inhibit the process of thrombopoiesis persistently in
megakaryocytes, as detected by the long-lasting decrease in themembrane capacitance and the irreversible sup-
pression of the Kv1.3-channel currents. Chlorpromazine-induced changes in the membrane micro-architecture
are thought to be responsible for its persistent effects.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Chlorpromazine, one of the major phenothiazine-derived tranquil-
izers, is widely used in the treatment of psychiatric disorders for
which neuroleptic sedation is required [1]. The general side effects of
chlorpromazine primarily include those of the nervous system, such
as Parkinson-like symptoms, drowsiness, dizziness and occasionally
seizure [2]. However, previous studies also indicated a relatively higher
incidence of hematologic side effects [3,4], among which thrombocyto-
penia can often be severe and difﬁcult to treat [5,6]. As for the leading
mechanisms of drug-induced thrombocytopenia, drugs, such as nonste-
roidal anti-inﬂammatory drugs (NSAIDs) or antibiotics, stimulate the
production of auto-antibodies to proteinswithin the plateletmembranes,
and the antibodies then bind to the drug–protein complexes to destroy
the platelets [7,8]. However, we know little about the mechanisms by).which chlorpromazine causes severe and persistent thrombocytopenia
[9]. According to some clinical studies, the use of chlorpromazinewas as-
sociatedwith the development of agranulocytosis, which is characterized
by a decrease in the hematopoietic function [10,11]. These studies indi-
cated the presence of an as-yet-unknown mechanism in this drug-
induced thrombocytopenia, bywhich the platelet production frommega-
karyocytes may directly be affected. In our recent study, chlorpromazine,
which partitions preferentially into the lipid bilayers of the plasmamem-
branes [12], induced membrane surface deformation in mast cells [13],
and thus modulated the process of exocytosis. Since degranulating mast
cells share common membranous features with megakaryocytes in that
they have many blebs on their cell surface [14], chlorpromazine would
also likely induce some structural changes on the membrane surface of
megakaryocytes and thus affect their thrombopoietic activity. To test
this, employing the standard patch-clamp whole-cell recording tech-
nique in rat megakaryocytes, we examined the effects of chlorpromazine
on the membrane capacitance and Kv1.3-channel currents. By electron
microscopic imaging of the cellular surface, we also examined the effects
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show for the ﬁrst time that chlorpromazine persistently inhibits the
process of thrombopoiesis in megakaryocytes, as detected by the
long-lasting decrease in the membrane capacitance and the irrevers-
ible suppression of the Kv1.3-channel currents. We also show that
the chlorpromazine-induced changes in the membrane micro-
architecture are responsible for its persistent effects.2. Materials and methods
2.1. Cell sources and preparation
MaleWistar rats more than 25weeks old, supplied by Japan SLC Inc.
(Shizuoka, Japan), were deeply anesthetized with isoﬂurane and then
killed by cervical dislocation. The protocol for animal use was approved
by the Animal Care and Use Committee of Tohoku University Graduate
School of Medicine. Single megakaryocytes were isolated from rat
bone marrow as described in our previous studies [15,16]. Brieﬂy,
bone marrow obtained from femoral bones was ﬂushed with standard
external (bathing) solution containing (in mM): NaCl, 145; KCl, 4.0;
CaCl2, 1.0; MgCl2, 2.0; HEPES, 5.0; bovine serum albumin, 0.01% (pH 7.2
adjusted with NaOH), and dispersed by repetitive pipetting. After re-
moving large pieces of tissue, the cells were washed twice by gentle
centrifugation for a minute and resuspended in the standard external
solution. Megakaryocytes were easily distinguishable from other bone
marrow cells by their large size andmultilobed nucleus [17], as demon-
strated in our previous studies [15,16,18]. The isolated megakaryocytes
were maintained at room temperature (22–24 °C) for use within 8 h.2.2. Di-8-ANEPPS staining
After incubating single megakaryocytes in the external solution at
room temperature, theywere further incubated for 30min in an external
solution containing styryl membrane indicator, di-8-ANEPPS (Biotium,
Hayward, Calif., USA; ﬁnal concentration 20 μM), as previously described
[16]. Chlorpromazine was then added to reach a ﬁnal concentration of
100 μM. Fluorescent images were taken using a TE 2000-E Nikon Eclipse
confocal microscope (Nikon, Tokyo, Japan).2.3. Lucifer yellow trapping on the cell surface
Single megakaryocytes were incubated in the external solutions
containing no drug or 100 μM chlorpromazine. As a positive control,
mast cells were isolated from rat peritoneal cavity and exocytosis was
externally induced by compound 48/80 (10 μg/ml) [13,19]. Then, they
were incubated for 5 min at room temperature in the external solution
containing a hydrophilic ﬂuorescent dye, lucifer yellow (Wako, Osaka,
Japan; ﬁnal concentration 10 μM) [13,19,20], and were washed 2 to 3
times thoroughly with dye-free external solutions. Fluorescent images
were taken using a TE 2000-E Nikon Eclipse confocal microscope.2.4. Electrical setup and patch-clamp recordings
We conducted standardwhole-cell patch-clamp recordings using an
EPC-9 patch-clamp ampliﬁer system (HEKA Electronics, Lambrecht,
Germany) as described previously [15,16,21,22]. The patch pipette re-
sistance was 1–3 MΩwhen ﬁlled with internal (patch pipette) solution
containing (in mM): KCl, 145; MgCl2, 1.0; EGTA, 10; Hepes, 5.0 (pH 7.2
adjusted with KOH). After the giga-seal formation, we applied suction
brieﬂy to the pipette to rupture the patch membrane. The series resis-
tance of the whole-cell recordings was maintained below 10 MΩ during
the experiments. All experiments were carried out at room temperature.2.5. Drug delivery
Chlorpromazine hydrochloride, purchased from Wako Pure Chem
Ind. (Osaka, Japan), was dissolved in the external solution at a ﬁnal
concentration of 100 μM. This amphiphilic drug can be relatively hydro-
philic depending on their doses and the conditions of the solvent water,
such as its pH and temperature [23]. With the doses we used and the
external solution we prepared in the present study (pH 7.2, at room
temperature), chlorpromazine was easily dissolved in the solution
without the need of lipophilic drug vehicles, such as dimethyl sulfoxide
(DMSO). Therefore, as a control, we applied the external solution alone
to the cells, and comparedwith those containing either concentration of
the drug.We delivered the reagent to the cells by a standing hydrostatic
pressure of 3 cmH2O from a nearby pipette as described previously
[16,21,22]. Then, whole-cell membrane currents were recorded before
and after 1 min exposure to the drug and after a 2 min washout. To rule
out the possibility that the observed effect just resulted from the proce-
dure of the reagent application, we simply applied the external solution
to the cells and conﬁrmed the absence of any signiﬁcant changes in the
channel currents (Fig. 4A).
2.6. Membrane capacitance measurements
To measure the membrane capacitance of the megakaryocytes, we
employed a sine plus DC protocol using the Lock-in ampliﬁer of the
EPC-9 Pulse program, as described previously [13,16,19,21,22]. An
800-Hz sinusoidal command voltage was superimposed on a holding
potential of −80 mV. The membrane capacitance (Cm), as well as
membrane conductance (Gm) and series conductance (Gs), was contin-
uously recorded before and after 30 s exposure to salicylate during the
whole-cell recording conﬁguration. Speciﬁc Cmwas expressed per unit
spherical cell surface area (μF/cm2).
2.7. Electron microscopy
The megakaryocytes, incubated in the external solutions containing
no drug or 100 μM chlorpromazine for 10 min, were ﬁxed with 4%
paraformaldeyde and 3% glutaraldehyde in 0.1 M cacodylate buffer,
pH 7.4 for 2 h at room temperature. After being trimmed into small
pieces, the above specimen containing the cells was postﬁxed in 1%
osmium tetroxide for 1 h at 4 °C, rinsed in PBS, dehydrated in a graded
series of alcohol and propylene oxide, and ﬁnally embedded in epoxy
resin. Ultrathin (80 nm) sections were prepared on an ultramicrotome
(Ultracut R, Leica, Heerbrugg, Switzerland) with a diamond knife and
then were stained with uranyl acetate and lead citrate, and viewed
using an electron microscope (JEM-1200, JOEL, Tokyo, Japan).
2.8. Statistic analyses
Data were analyzed using PulseFit software (HEKA Electronics,
Lambrecht, Germany), IGOR Pro (WaveMetrics, Lake Oswego, Oreg.,
USA) and Microsoft Excel (Microsoft Corporation, Redmond, Wash.,
USA) and reported as means ± SEM. Statistical signiﬁcance was assessed
by two-way ANOVA followed by Dunnett's or Student's t test. A value of
P b 0.05 was considered signiﬁcant.
3. Results
3.1. Effects of chlorpromazine on membrane architecture of
rat megakaryocytes
The physiological and therapeutic levels of chlorpromazine ranged
from 1 to 10 μM in previous in vitro studies [24], although concentra-
tions as high as 1mMwere required for the drug to protect the erythro-
cytes from hypotonic lysis [25,26]. Additionally, in our recent study
using mast cells, chlorpromazine at a concentration of 100 μM was
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curvature of the cells [13]. Therefore, we selected this dose in the pres-
ent study. Consistent with the previous ﬁndings demonstrated in outer
hair cells [12], chlorpromazine induced deformation of the membrane
surface in red blood cells (Fig. 1Ab vs a). Such an effect of chlorproma-
zine may be ascribable to its pharmacological property as a positively
charged membrane amphipath [12,13,27], which is partitioned prefer-
entially into the inner leaﬂet of the plasmamembrane and generates in-
ward membrane bending (Fig. 1Ac).
Chlorpromazine, however, similar to the effects of salicylate in our re-
cent study [18], did not affect the general appearance of megakaryocytes,
well preserving a number of wrinkles on their cell surface (Fig. 1Bb vs a).
The initial process of thrombopoiesis in megakaryocytes is featured byFig. 1. Effects of chlorpromazine on membrane architecture of megakaryocytes. A: (a, b)
Differential-interference contrast (DIC) microscopic images of red blood cells before (a)
and after incubation in the external solution containing 100 μM chlorpromazine
(b). (c) Illustrations of the chlorpromazine-induced plasma membrane curvature in
red blood cells. Positively charged chlorpromazine is partitioned preferentially into the
negatively charged inner leaﬂets of the lipid bilayers and generates inward membrane
bending (left). It induces inner leaﬂet expansion in red blood cells (right). B: (a, b) DIC
microscopic images of megakaryocytes before (a) and after incubation in the external
solution containing 100 μM chlorpromazine (b). (c, d) Confocal ﬂuorescence images of
di-8-ANEPPS-labeled megakaryocytes before (c) and after incubation in the external
solution containing 100 μM chlorpromazine (d). (e–g) The trapping of the ﬂuorescent
dye (lucifer yellow) on the cell surface was detected in degranulating mast cells (e) and
megakaryocytes incubated in the external solutions containing no drug (f) or 100 μM
chlorpromazine (g).the invagination of the plasmamembranes, which provides the extracel-
lular space required for the formation of pro-platelets [28–30]. Therefore,
the wrinkles on the megakaryocyte surface were thought to represent
the membrane surface deformation as a result of thrombopoiesis.
Di-8-ANEPPS is a lipophilic membrane potential ﬂuorescent dye,
which is incorporated into the outer leaﬂet of the plasma membrane
[31]. In our previous studies, we actually used this dye to detect the
membrane architecture of megakaryocytes [15,16,18]. In the present
study, to examine the effects of chlorpromazine on the membrane
surface deformation in megakaryocytes, we stained the cells with di-
8-ANEPPS. In megakaryocytes incubated in the external solution, the
dye penetrated deep into the cells and stained throughout the extranu-
clear cellular volume (Fig. 1Bc), indicating the creation of folds in the
membranes during thrombopoiesis [28–30]. On the other hand, lucifer
yellow is a water-soluble and membrane-impermeable ﬂuorescent
dye, which is retained in the invaginated folds created in the plasma
membranes [20,32]. In degranulating mast cells, the dye was retained
in the opened pores formed by exocytosis (Fig. 1Be), as we previously
demonstrated [13,19]. However, in megakaryocytes incubated in the
external solution, the dye was completely washed out (Fig. 1Bf), indi-
cating that the folds created in themembranes did not form the opened
pores on the cell surface. The external addition of chlorpromazine or the
incubation with this drug did not affect these ﬁndings obtained from
either di-8-ANEPPS staining or lucifer yellow trapping (Fig. 1Bd vs. c
and g vs. f). These results suggested that chlorpromazine failed to induce
morphological changes in themembrane architecture ofmegakaryocytes.
3.2. Effect of chlorpromazine on whole-cell membrane capacitance in rat
megakaryocytes
As shown in Fig. 1B, our results did not provide morphological evi-
dence that chlorpromazine may affect the membrane architecture of
megakaryocytes (Fig. 1B). Nevertheless, since chlorpromazine is amphi-
philic [12,13,27] and is known to interact with the lipid bilayers of the
plasmamembrane [33], this drugwould likely generate somemicroscop-
ic changes in the megakaryocyte membrane surface. In our previous
studies, microscopic changes in the cell surface areawere bestmonitored
in thymocytes ormast cells bymeasurement of thewhole-cellmembrane
capacitance (Cm) [13,19,21,22,34,35]. Therefore, in the present study, we
employed this electrophysiological approach to detect the microscopic
changes in the megakaryocyte membrane surface (Fig. 2). Numerical
changes in the speciﬁc Cm expressed per unit spherical cell surface area
(μF/cm2) are summarized in Table 1. By simply applying the external
solution alone tomegakaryocytes (Fig. 2A), we conﬁrmed that our proce-
dure of reagent application, a puff application by constant hydrostatic
pressure with a nearby pipette, was without signiﬁcant effects on the
Cm and the other parameters, such as membrane conductance (Gm)
and series conductance (Gs) (Fig. 2A, Table 1).
According to previous in vitro studies or clinical studies in humans
[24,33,36], the physiological and therapeutic concentrations of chlor-
promazine ranged from 1 to 10 μM. However, in several in vitro studies,
including ours [13], single cells sometimes required higher concentra-
tions of this drug, such as 100 μM or up to 1 mM, to effectively elicit its
pharmacological properties [12,25,26,37]. Additionally, in the present
study, since we delivered chlorpromazine by a puff application method,
there was the possibility of partial and insufﬁcient exposure of the drug
to the cells. Therefore, we applied signiﬁcantly higher concentrations of
this drug to the isolated megakaryocytes, starting from 1 mM to 10 μM
(Fig. 2B and C, Table 1). The pipette inclusion of 1 mM chlorpromazine
induced a rapid and marked decrease in the Cm immediately after the
application (Table 1). However, it subsequently caused erratic changes
in the Gm and Gs, which made the further measurement of the Cm less
reliable [38,39]. The inclusion of 100 μM chlorpromazine also markedly
decreased the Cm immediately after its application (Fig. 2B, Table 1).
However, it did not cause any signiﬁcant changes in the Gm and Gs
(Fig. 2B), and the effect of this drug was persistent after withdrawal of
Fig. 2. Chlorpromazine-induced changes in megakaryocyte membrane capacitance, series
and membrane conductance. After establishing the whole-cell conﬁguration, external so-
lutions containing no drug (A), 100 μM (B) and 10 μM chlorpromazine (C) were delivered
for 30 s to single megakaryocytes. Membrane capacitance, series and membrane conduc-
tanceweremonitored for at least 150 s. N=5 for each trace. Cm, membrane capacitance;
Gs, series conductance and Gm, membrane conductance.
Table 1
Summary of changes in membrane capacitance after application of chlorpromazine.
Agents N Cm before drug application (μF
External solution (control) 5 9.52 ± 0.78
1 mM Chlorpromazine 5 9.81 ± 0.30
100 μM Chlorpromazine 5 10.1 ± 1.22
10 μM Chlorpromazine 5 10.4 ± 0.45
Values are means ± SEM. Cm= speciﬁc membrane capacitance.
# P b 0.05 vs. Cm before drug application.
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chlorpromazine did not signiﬁcantly change the Cm (Fig. 2C, Table 1),
nor did it signiﬁcantly affect the other parameters (Fig. 2C).
In the present study, as shown in our previous studies using mega-
karyocytes or mast cells [13,16,18,19], an 800-Hz sinusoidal command
voltage was continuously superimposed on the holding potential
of −80 mV during the measurement of Cm. However, immediately
after the internalization of GTP-γ-S, the Gs tended to be slightly
decreased (Fig. 2), reﬂecting a gradual increase in the series resistance be-
tween the pipette electrodes and the cells interior. Nevertheless, despite
such initial decrease, the Gs remained high during the observation period
(N125 nS), indicating that the series resistance remained properly low
(b8 MΩ). Additionally, this parameter was not signiﬁcantly affected by
the application of chlorpromazine (Fig. 2), suggesting that the cells
were accurately voltage-clamped during the measurement of Cm. In
the present study, the drug did not inﬂuence the Gm either (Fig. 2),
maintaining its level below 10 nS during the observation period. Since
theGmvalue usually correlateswith the ionic permeability of themem-
brane [39], the megakaryocyte membranes were not considered to be
damaged during themeasurement of Cm [38]. Therefore, the results ob-
tained from the Cmmeasurement accurately indicated that chlorprom-
azine almost irreversibly induced microscopic structural changes in the
megakaryocyte membrane surface, which was not morphologically
detected by the differential-interference contrast (DIC) microscopy or
the ﬂuorescent imaging techniques (Fig. 1B). In megakaryocytes, since
the value of speciﬁc Cm reﬂects the number of invaginated plasma
membranes during thrombopoiesis [15,16,18,31], the decrease in the
Cm suggested a decrease in the thrombopoietic activity caused by
chlorpromazine.3.3. Electron microscopic images of chlorpromazine-induced changes in
membrane micro-architecture of megakaryocytes
From our results, chlorpromazine was likely to induce microscopic
structural changes in the megakaryocyte membrane surface (Fig. 2),
and thus may affect the micro-architecture of the membrane. In the
present study, however, we could not detect such changes by using
DIC microscopy or the ﬂuorescent imaging technique (Fig. 1B). There-
fore, we took the electron microscopic images of megakaryocytes after
incubating the cells in external solution containing no drug or 100 μM
chlorpromazine (Fig. 3). On the membrane surface of megakaryocytes
incubated in the external solution, there were a number of ﬁne protru-
sions of pseudopodia (Fig. 3A), which were in the middle of the elonga-
tion or the branching process, indicating the ongoing process of
thrombopoiesis [14,28,40]. However, in megakaryocytes incubated in
the chlorpromazine-containing solution, instead of the ﬁne protrusions
of the podia, there were bolder paddle-shaped protrusions on the bulg-
ing or dented structures of the membrane surface (Fig. 3B), with some
of their heads torn off the membranes. These results suggested that
chlorpromazine changed the micro-architecture of the megakaryocyte
membrane surface, whichwas likely to be associated with the impaired
process of pro-platelet formation./cm2) Cm after drug application (μF/cm2) ΔCm (μF/cm2)
9.29 ± 0.69 0.23 ± 0.12
5.23 ± 0.56# 4.58 ± 0.68
3.41 ± 1.68# 6.72 ± 0.86
10.9 ± 0.68 0.50 ± 0.28
Fig. 3. Electron microscopic images of chlorpromazine-induced changes in membrane
micro-architecture in megakaryocytes. Thin-section electron micrographs of megakaryo-
cyte plasma membranes after incubating the cells in the external solutions containing
no drug (A) or 100 μM chlorpromazine (B). Low-power (left) and high-power (right)
views.
Fig. 4. Effects of chlorpromazine on Kv1.3 channel currents in rat megakaryocytes.
Effects of the external solutions containing no drug (A) and 100 μM chlorpromazine
(B). A, Ba: typical whole-cell current traces at different voltage-steps recorded before and
after the reagent application. The currents were elicited by voltage-steps from a holding
potential of−80 mV to 0 or 40 mV, as depicted in the voltage protocols. Each pulse was
applied for a 200-ms duration between 10-s intervals. Bb: peak current ampliﬁcations ob-
tained from the records in a at a voltage-step of 40 mV. Bc: pulse-end current ampliﬁca-
tions obtained from the records in a at a voltage-step of 40 mV. #P b 0.05 vs. before the
reagent application. Values are means ± SEM (n = 6). Differences were analyzed by
ANOVA followed by Dunnett's or Student's t test.
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rat megakaryocytes
Megakaryocytes or platelets express a variety of K+-channels,
Ca2+-channels and Cl−-channels in their plasma membranes. They
include voltage-gated K+-channels (Kv1.3) [16,41], Ca2+-activated
K+-channels (KCa3.1) [42], ATP-gated P2X1 receptors [43], melastin-
like transient receptor potential 2 (TRPM2) [44], pannexin-1 [45] and
transmembrane protein 16F (TMEM16F) [46]. Among them, megakar-
yocytes most predominantly express Kv1.3 [16,41] and the channel is
mainly responsible for facilitating the calcium inﬂux necessary to stim-
ulate the megakaryocyte activity [41,47]. Therefore, in the present
study, to determine the involvement of Kv1.3-channels in the effects of
chlorpromazine (Figs. 2 and 3), we applied external solution containing
100 μM chlorpromazine to megakaryocytes and examined the changes
in the whole-cell currents (Fig. 4). Stepwise changes in the membrane
potential, from the holding potential of −80 mV to the various
depolarizing potential levels, evoked membrane currents in the mega-
karyocytes, showing a voltage-dependent activation and inactivation pat-
tern characteristic to Kv1.3 (Fig. 4A) [16,41,48,49]. As we previously
demonstrated the inhibitory effects of the drugs, such as dihydropyridine
Ca2+ antagonists, HMG-CoA reductase inhibitors and macrolide antibi-
otics, on the thymocyte Kv1.3-channels [21,22,34,35], chlorpromazine al-
most totally inhibited the Kv1.3-channel currents in megakaryocytes
(Fig. 4Ba). It both markedly lowered the peak (from 5.22 ± 0.92 to
0.23 ± 0.04 nA, n = 6, P b 0.05, Fig. 4Bb) and the pulse-end currents
(from 2.76 ± 0.60 to 0.26 ± 0.06 nA, n= 6, P b 0.05, Fig. 4Bc). Despite
the withdrawal of the drug, however, the inhibited currents did not re-
cover during the observation period (Fig. 4Ba–c), which was consistent
with the ﬁndings obtained from the Cm measurements (Fig. 2B). These
results indicated that chlorpromazine almost irreversibly inhibited theKv1.3-channel currents in megakaryocytes when it modulated the
thrombopoietic activity of the cells.
4. Discussion
In ourmost recent study, we demonstrated that salicylate reversibly
inhibited the process of thrombopoiesis in rat megakaryocytes [18].
In our previous study, since salicylate and chlorpromazine, as a
negatively- or positively-charged membrane amphipath, exerted
contrastive effects on mast cell plasma membranes [13], we examined
the effects of chlorpromazine on megakaryocyte membranes in the
present study. Similar to salicylate [18], chlorpromazine was likely to
suppress the thrombopoietic activity of megakaryocytes with signiﬁcant
decreases in their membrane capacitance (Fig. 2). However, differing
fromsalicylate, chlorpromazine persistently decreased themembrane ca-
pacitance and suppressed the Kv1.3-channel currents (Figs. 2 and 4), in-
dicating that the drugmay almost irreversibly inhibit the thrombopoietic
activity. Due to its higher partition coefﬁciency, chlorpromazine binds
easily and thus interacts with the lipid bilayers of the plasmamembranes
in red blood cells or outer hair cells [37,50–52]. According to our previous
studies, highly lipophilic drugs, such as benidipine and simvastatin, dis-
persed easily into the thymocyte plasma membranes and accumulated
between the lipid bilayers, and thus exerted long-lasting suppressive
effects on the channel currents and the membrane capacitance [21,34].
Megakaryocyte membranes share common biophysical features with
Fig. 5. Illustrations of the chlorpromazine-induced plasma membrane curvature and the
proposed effects on thrombopoiesis in megakaryocytes. A: Positively charged chlorprom-
azine is partitioned preferentially into the inner leaﬂet of the lipid bilayers. It induces inner
leaﬂet expansion and generates inward membrane bending. B: On the surface of the
pseudopodia,which protrude from themegakaryocytemembrane during thrombopoiesis
(a), such induced inward membrane stretch (blue arrows) would mechanically shorten
and widen the heads of the podia (b), thereby halting their further elongation or the
branching process required for the pro-platelet release. On the ﬂat parts between the
pseudopodia (a), the inward stretch of the membranes (blue arrows) would narrow the
necks of thewidened podia (b), sometimes tearing the heads off themembrane. The inward
stretch on the ﬂat parts would also generate the bold dented structures on the membrane
surface (b) and mechanically disturb the cytoskeletal rearrangements required for the pro-
platelet formation (b).
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cell surface, which are deeply associated with their exocytotic release of
microparticles or secretory granules [14]. Recently, using rat peritoneal
mast cells, we have actually demonstrated that chlorpromazine,
which generates inward membrane bending [19], morphologically
counteracted themembrane surface deformation induced by exocytosis
and signiﬁcantly suppressed the increase in the membrane capacitance
[13]. In this context, the strong afﬁnity of chlorpromazine with the
plasma membranes may also be responsible for its persistent suppres-
sion of the channel currents and the membrane capacitance observed
in megakaryocytes.
Mathematically, a whole-cell Cm, which can be measured by the
electrophysiological method, is calculated from a parallel-plate capacitor
formula: Cm = εA / d, where ε is the dielectric modulus of the plasma
membrane; A, the membrane surface area and d, the membrane thick-
ness [53]. Assuming that ε and d are relatively constant under a physio-
logical condition, the changes in Cm are primarily considered to be
ascribable to the changes inA [54]. Therefore, as previously demonstrated
in our study [16], the value of speciﬁc Cm inmegakaryocytes reﬂects the
number of invaginated folds in the plasma membranes as a result of
thrombopoiesis [15,31]. In the present study, using this electrophysio-
logical approach, we demonstrated for the ﬁrst time that chlorproma-
zine decreased the number of invaginated folds in the megakaryocyte
membranes (Fig. 2). By showing the indirect evidence that chlorprom-
azine is likely to inhibit the process of thrombopoiesis, our ﬁndings re-
vealed a novel mechanism of this drug-induced thrombocytopenia. The
irreversible effect of chlorpromazine on the decreased Cm (Fig. 2B)may
be responsible for the therapeutic difﬁculties of this drug-induced
thrombocytopenia and its prolonged clinical symptoms [5,6].
In the present study, chlorpromazine actually induced changes in
the membrane micro-architecture of megakaryocytes as shown by the
electron microscopy (Fig. 3). In many types of secretory cells, the exocy-
totic process can bemodulated bymechanical stimuli, such as changes in
the membrane tension, shear stress, hydrostatic pressure and compres-
sion [55]. Therefore, the chlorpromazine-induced changes in the mem-
brane micro-architecture of megakaryocytes may also contribute to its
inhibitory effect on thrombopoiesis. As we schematized in Fig. 5A, chlor-
promazine, a positively charged membrane amphipath, is partitioned
preferentially into the inner leaﬂet of the lipid bilayers. As we previously
demonstrated in rat peritoneal mast cells or recently proposed in adipo-
cytes [13,27], chlorpromazine induces inner leaﬂet expansion and gener-
ates inward membrane bending [12] (Fig. 5A). According to our recent
study, the inward membrane bending induced by a positively charged
lipophilic drug was actually detected in mast cells by using electron mi-
croscopy [19]. On the surface of the pseudopodia, which protrude from
themegakaryocytemembrane during thrombopoiesis (Fig. 5Ba), such in-
duced inward membrane stretch (blue arrows) would mechanically
shorten and widen the heads of the podia (Fig. 5Bb), thereby halting
their further elongation or the branching process required for the pro-
platelet release. On the ﬂat parts between the pseudopodia (Fig. 5Ba),
the inward stretch of the membranes (blue arrows) would narrow the
necks of the widened podia (Fig. 5Bb), sometimes tearing the heads off
the membrane. The torn heads of the pseudopodia may be associated
with the formation of “microparticles” from megakaryocytes [14],
which have recently been demonstrated to include active cellular frag-
ments, such as RNAs, lipid rafts andmembrane proteins [27]. The inward
stretch on the ﬂat parts (Fig. 5Ba) would also generate the bold dented
structures on the membrane surface (Fig. 5Bb) and mechanically disturb
the cytoskeletal rearrangements required for the pro-platelet formation
(Fig. 5Bb), which include the disassembly of centrosomes and the trans-
location of microtubules to the cellular cortex [29,40,56].
Since chlorpromazine is amphiphilic [12], it would induce drug–
membrane interactions after its penetration into the lipid bilayers of
the plasma membrane [33]. Then, in addition to disturbing lipid–lipid
interactions, chlorpromazine may directly perturb the composite
domains of the channels from inside the membrane. In our previousstudy, by actually measuring the intracellular Ca2+ concentration
([Ca2+]i) in mouse megakaryocytes, we revealed the physiological
mechanisms of the cellular function [47]. As an extension, the recent
study demonstrated in mouse megakaryocytes and platelets that
Kv1.3-channels expressed in these cells regulate agonist-evoked Ca2+
increases, inﬂuencing the numbers of circulating platelets [41]. In the
present study, we did not directly examine the changes in Ca2+ inﬂux
in response to the changes in K+ efﬂux through the Kv1.3-channels.
However, the previous studies strongly suggested that the [Ca2+]i in
megakaryocytes is mainly determined by the changes in the outward
K+ currents [41,47]. In this context, the [Ca2+]i in megakaryocytes
was thought to be decreased by the addition of chlorpromazine, since
thedrug almost totally and irreversibly inhibited the Kv1.3-channel cur-
rents in the present study (Fig. 4B). Here, we did not perform additional
patch-clampmeasurements to examine the activity of the other channels
expressed in megakaryocytes. However, these channels were thought to
be de-activated by the addition of chlorpromazine, since most of the cat-
ion or anion channels expressed in megakaryocytes are Ca2+-activated
[42–46]. According to an in vitro study using cultured megakaryocytes
[57], adenosine diphosphate (ADP)-induced spreading or shape changes
were primarily dependent on the Ca2+ signaling. Since such morpholog-
ical changes in megakaryocytes are deeply associated with the pro-
2811I. Kazama et al. / Biochimica et Biophysica Acta 1848 (2015) 2805–2812platelet formation [29,40,56], the decrease in the [Ca2+]i in megakaryo-
cytes may also additionally affect the chlorpromazine-induced inhibition
of thrombopoiesis.
In summary, this study demonstrated for the ﬁrst time that chlor-
promazine is likely to inhibit the process of thrombopoiesis persistently
in megakaryocytes, as detected by the long-lasting decrease in the
membrane capacitance and the irreversible suppression of the Kv1.3-
channel currents. The chlorpromazine-induced changes in the mem-
brane micro-architecture are thought to be primarily responsible for
its persistent effects.
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